Advertisement
Cardiovascular
Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs

May 5, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- A new position statement released today by the Society for Cardiovascular Angiography and Interventions (SCAI) calls for changes in the way quality of percutaneous coronary intervention (PCI, also known as angioplasty) care is measured and publically reported....

SCAI Announces National Quality Program to Improve Cardiovascular Patient Care

May 5, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- Today at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions, SCAI announced its national quality improvement program to measure and improve quality in the cath lab for better patient care. Building on its legacy of using...

New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients

May 5, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- New data presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions are the first to look at the use of highly specialized signals within implantable cardioverter defibrillators (ICDs) to detect restricted blood...

Advertisement

HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting

May 5, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- A substance secreted by the heart that is associated with congestive heart failure and renal failure is not predictive of reduction in systolic blood pressure in patients treated with renal artery stenting, according to results from the HERCULES trial presented...

SCAI Releases First Report on Transradial Access for Angioplasty and Stenting

May 5, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- As interventional cardiologists increasingly perform angiography or angioplasty and stent procedures via radial (wrist) access versus femoral (groin or upper leg) access, it will be imperative to develop training and competency guidelines, according to the first...

Echo Therapeutics Expands Into New Headquarters in Philadelphia

May 5, 2011 6:38 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, May 5, 2011 /- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today...

Resource Now Available to Help Clinicians Reduce Risk of Blood Exposure from Short Peripheral IV Catheter Insertion

May 3, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

SANDY, Utah, May 3, 2011 /- Healthcare workers now have the ability to better identify risks for exposure to bloodborne pathogens, take precautions to better protect themselves, and share information and experiences as a result of a new program developed by BD Medical, a segment of BD...

Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference

May 3, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., May 3, 2011 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer,  will present at the Bank of America Merrill Lynch 2011 Health...

Advertisement

CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation

May 3, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

ATLANTA and IRVINE, Calif., May 3, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the completion of its tender offer, through its wholly owned subsidiary CL Falcon, Inc., for 49.9 percent of the...

NMT Medical, Inc. Assigned All Its Assets to Joseph F. Finn, Jr., C.P.A. of the Firm Finn, Warnke & Gayton, LLP on April 20, 2011

May 2, 2011 9:33 am | by Bio-Medicine.Org | News | Comments

WELLESLEY HILLS, Mass., May 2, 2011 /- On April 20, 2011, NMT Medical, Inc. ("NMT Medical") assigned all its assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of NMT Medical creditors. NMT Medical's intellectual...

Boston Scientific Announces Its Schedule for Heart Rhythm Society Scientific Sessions

May 2, 2011 4:34 am | by Boston Scientific | News | Comments

NATICK, Mass., May 2, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced its schedule of major events and sponsored research at the 32nd Annual Scientific Sessions of the Heart Rhythm Society (HRS)

Abaxis Appoints Vernon Altman to Board of Directors

May 2, 2011 3:36 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., May 2, 2011 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced Vernon Altman has been appointed to the Company's Board of Directors, effective immediately. The addition of Mr. Altman brings...

Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies

May 2, 2011 1:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 2, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Drug Delivery in Central Nervous System Diseases - technologies,markets and companies...

Advertisement

Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration

April 28, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, April 28, 2011 /- A new study published online today in The New England Journal of Medicine ( NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD)....

SUPERA VERITAS® Receives Regulatory Approval in Australia

April 28, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

WEBSTER, Texas, April 28, 2011 /- IDEV Technologies, Inc. (IDEV) today announced the firm has received approval from the Therapeutic Goods Administration (TGA), Australia's regulatory agency for medical drugs and devices, for the SUPERA VERITAS® stent system for use in biliary and...

CryoLife Posts Record Quarterly Revenues of $30.2 Million

April 28, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

ATLANTA, April 28, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the first quarter of 2011.  Revenues for the first quarter increased 2 percent to a quarter record of $30.2...

Cardica to Announce Fiscal 2011 Third Quarter Financial Results on Tuesday, May 10, 2011

April 28, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif., April 28, 2011 /- Cardica, Inc. (Nasdaq: CRDC ) today announced that it will release financial results for its fiscal third quarter ended March 31, 2011, on Tuesday, May 10, 2011, after the markets close. Cardica's management will host a conference call at 4:30 p.m....

AMETEK ACQUIRES AVICENNA TECHNOLOGY

April 28, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

BERWYN, Pa., April 28, 2011 /- AMETEK, Inc. (NYSE: AME ) today announced that it has acquired Avicenna Technology, Inc., a privately held supplier of custom, fine-featured components used in the medical device industry.  Avicenna Technology with its headquarters and manufacturing...

Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session

April 28, 2011 12:33 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., April 28, 2011 /- Rhythmia Medical Inc., announced today that key results from its ongoing pre-clinical and clinical studies will be presented at the 2011 Annual Scientific Session of the Heart Rhythm Society in San Francisco, CA. The results will highlight the...

NxStage Medical names Miller to new international growth role

April 27, 2011 10:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

NxStage Medical Inc., a Lawrence maker of dialysis products, has named Michael Miller Jr. to the new post of president, international. In the new position, he will be charged with promoting NxStage's global growth in the European Union, Asia-Pacific and the Middle East.

NxStage® Names Michael Miller, Jr. President, International

April 27, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

LAWRENCE, Mass., April 27, 2011 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced that Michael Miller, Jr., former Senior Vice President and General Manager of the Cardiac Care Business at Philips Healthcare, has joined the...

Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results

April 26, 2011 11:33 pm | by Bio-Medicine.Org | News | Comments

SEATTLE, April 27, 2011 /- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported accomplishments and financial results for the first quarter ended March 31, 2011. "In the first quarter, we raised $50 million through two financings, advanced pixantrone into...

Idera stock drops on hepatitis-C drug delay

April 26, 2011 6:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Idera Pharmaceuticals Inc.'s stock dropped more than 5 percent Monday, following the company's announcement that it would delay the launch of a clinical trial on its drug candidate for hepatitis C.

Boston Scientific Announces FDA Approval and U.S. Launch of IONâ„¢ Platinum Chromium Stent System

April 25, 2011 4:33 am | by Boston Scientific | News | Comments

Innovative alloy designed to improve new coronary stent's acute performance

Stereotaxis to Present at Upcoming Investor Conferences

April 25, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, April 25, 2011 /- Stereotaxis, Inc. (NASDAQ: STXS ) today announced that executive management will present at the following investor conferences during May 2011: The Deutsche Bank Annual Health Care Conference in Boston.  Michael P. Kaminski, President and Chief Executive...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading